Related Experiment Video
Updated: Jun 3, 2026
08:11
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
Published on: July 6, 2013
An optimized engineered bacterium for tyrosinemia type 1 therapy: A multi-species preclinical study
Peng Gu1, Yunfei Zhao1, Jiajia Hu1
1Department of Pathophysiology, Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Summary
Engineered probiotics offer a novel treatment for hereditary tyrosinemia type 1 (HT1), a serious metabolic disorder. This innovative therapy effectively reduces toxic tyrosine buildup and improves disease symptoms in preclinical models.
Area of Science:
- Biotechnology
- Metabolic Disorders
- Microbiome Therapeutics
Background:
- Hereditary tyrosinemia type 1 (HT1) is a severe metabolic disorder characterized by toxic tyrosine accumulation.
- Current treatments, nitisinone (NTBC) and diet, present lifelong burdens and side effects.
Purpose of the Study:
- To develop and evaluate an engineered probiotic, e-EcN-HT, as a novel therapeutic for HT1.
- To assess the efficacy and safety of e-EcN-HT across multiple animal models of HT1.
Main Methods:
- Development of an optimized engineered probiotic (e-EcN-HT).
- Preclinical testing in FAH-/- mice, FAH-/- rabbits, and Bama minipigs.
- Evaluation of tyrosine metabolism and safety assessments.
Main Results:
- e-EcN-HT mitigated acute and chronic manifestations of HT1 in mice and rabbits.
- The probiotic demonstrated effective tyrosine metabolism in pigs.
- Comprehensive safety assessments confirmed e-EcN-HT was well-tolerated without adverse effects.
Conclusions:
- Engineered probiotics represent a promising therapeutic strategy for hereditary tyrosinemia type 1.
- e-EcN-HT shows significant potential for treating HT1 and other metabolic disorders.
Related Concept Videos
01:22Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...